DaxibotulinumtoxinA (“daxi”) is an investigational Botox®-like drug produced by the company Revance. Oregon Medical Research Center (OMRC) and our patient volunteers participated in a large national study funded by Revance where daxi was investigated for its ability to remove glabellar fold lines, the often-deep, perpendicular, skin wrinkles seen between the eyes. Over 3,000 patients were […]
Ilumya(TM) (tildrakizumab-asmn) is a new medication recently approved by the F.D.A. for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. We’ve partnered with patients for nearly 6 years on studies that have helped provide the data to show the outstanding results for patients on this treatment. We […]
We are excited to announce that one of the clinical studies that we and our patients participated in met its ultimate goal: approval by the Federal Drug Administration (FDA). Qbrexza cloths will be available as a prescription beginning in October 2018. Qbrexza cloths are the first new treatment for hyperhidrosis (excessive sweating) since 2011 and […]
If you have psoriasis, it places you at a higher risk for having a heart attack when compared to someone who doesn’t have psoriasis. The old saying from a 1970’s TV commercial, “the heartbreak of psoriasis,” is true! If you have a little bit of psoriasis, then the risk is a little bit. If you […]
In a December 2016 issue of New England Journal of Medicine, and a May 2017 issue of Lancet, two of the world’s most prominent medical journals, OMRC’s Dr. Andrew Blauvelt and colleagues reported the results of phase 3 studies using dupilumab (also known as Dupixent) for the treatment of moderate-to-severe atopic dermatitis (also known as […]
Biosimilars are biologic medications that are near identical, or similar, copies of original FDA-approved biologic medications. Some people view them as “generic biologics,” although technically they are not generic drugs, since generics are 100% identical to original medications. In this article published in the magazine Dermatology World, the current state of biosimilars is discussed, especially […]
